Verrica Pharmaceuticals, Inc. (VRCA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1240938,
    "name": "Verrica Pharmaceuticals, Inc.",
    "stock_name": "Verrica Pharmaceuticals, Inc.",
    "full_name": "Verrica Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/verrica-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "8.42",
    "chg": 1.69,
    "chgp": "25.11%",
    "dir": 1,
    "prev_price": "6.73",
    "mcapval": "47.85",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US92511W1080",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "390.66 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/verrica-pharmaceuticals-inc-1240938-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Verrica Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-verrica-pharmaceuticals-inc-technically-bullish-or-bearish-3547558",
        "imagepath": "",
        "date": "2025-09-20 19:58:11",
        "description": "As of 9 September 2025, the technical trend for Verrica Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a mildly bullish MACD on both weekly and monthly time frames, and a bullish monthly RSI. However, the daily moving averages are bearish, and both the Bollinger Bands and KST indicators are bearish on a monthly basis. Additionally, the Dow Theory shows a mildly bearish stance on both weekly and monthly time frames. \n\nThe stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a 1-year return of -78.16% versus the S&P 500's 17.14%...."
      },
      {
        "title": "Is Verrica Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-verrica-pharmaceuticals-inc-overvalued-or-undervalued-3543893",
        "imagepath": "",
        "date": "2025-09-20 18:31:52",
        "description": "As of 7 November 2022, Verrica Pharmaceuticals, Inc. has moved from a grade of does not qualify to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a Price to Book Value of -3.05, an EV to EBIT of -1.25, and an EV to EBITDA of -1.28, indicating significant negative valuations compared to traditional benchmarks.\n\nIn comparison to peers, Verrica's valuation ratios are less favorable, with Gossamer Bio, Inc. showing a P/E of -4.3771 and an EV to EBITDA of -4.1514, while Rigel Pharmaceuticals, Inc. is very attractive with a P/E of 7.4943 and an EV to EBITDA of 6.4016. The stark contrast in these ratios highlights Verrica's challenging position within the industry. Additionally, the company's stock has significantly underperformed against the S&P 500, with a one-year return of -78.16% compared to the index's 17.14%, reinforcing the view of overvaluation...."
      }
    ],
    "total": 7,
    "sid": "1240938",
    "stock_news_url": "https://www.marketsmojo.com/news/verrica-pharmaceuticals-inc-1240938"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Verrica Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:58:11

As of 9 September 2025, the technical trend for Verrica Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a mildly bullish MACD on both weekly and monthly time frames, and a bullish monthly RSI. However, the daily moving averages are bearish, and both the Bollinger Bands and KST indicators are bearish on a monthly basis. Additionally, the Dow Theory shows a mildly bearish stance on both weekly and monthly time frames. The stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a 1-year return of -78.16% versus the S&P 500's 17.14%....

Is Verrica Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:31:52

As of 7 November 2022, Verrica Pharmaceuticals, Inc. has moved from a grade of does not qualify to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a Price to Book Value of -3.05, an EV to EBIT of -1.25, and an EV to EBITDA of -1.28, indicating significant negative valuations compared to traditional benchmarks. In comparison to peers, Verrica's valuation ratios are less favorable, with Gossamer Bio, Inc. showing a P/E of -4.3771 and an EV to EBITDA of -4.1514, while Rigel Pharmaceuticals, Inc. is very attractive with a P/E of 7.4943 and an EV to EBITDA of 6.4016. The stark contrast in these ratios highlights Verrica's challenging position within the industry. Additionally, the company's stock has significantly underperformed against the S&P 500, with a one-year return of -78.16% compared to the index's 17.14%, reinforcing the view of overvaluation....

View All News